Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,590   -0,027   (-4,38%) Dagrange 0,574 - 0,609 437.420   Gem. (3M) 306,7K

Novacyt de volgende biotech raket!

70.511 Posts
Pagina: «« 1 ... 1540 1541 1542 1543 1544 ... 3526 »» | Laatste | Omlaag ↓
  1. Beso 16 oktober 2020 08:53
    quote:

    segri schreef op 16 oktober 2020 08:14:

    [...]

    De vraag is of Theradiag nog niet op z'n piek zit...
    Dat zei men ook van Novacyt al toen die op 5,7 gestaan had.
    Theradiag in 1 dag met 20% omhoog na berichten dat tests in de apotheek in Frankrijk te verkrijgen zijn. Met de corona cijfers zoals die nu gaan zie ik nog veel potentieel voor sneltests. Denk maar aan toerisme etc...
  2. fvmetelen 16 oktober 2020 09:29
    quote:

    Beso schreef op 16 oktober 2020 08:53:

    [...]
    Dat zei men ook van Novacyt al toen die op 5,7 gestaan had.
    Theradiag in 1 dag met 20% omhoog na berichten dat tests in de apotheek in Frankrijk te verkrijgen zijn. Met de corona cijfers zoals die nu gaan zie ik nog veel potentieel voor sneltests. Denk maar aan toerisme etc...
    Waar kan ik dit Theradiag kopen
  3. Zuurtje 16 oktober 2020 09:50
    Shares News
    Novacyt excites investors with strategic acquisition
    15 October 2020, 12:50
    Rapid diagnostics testing company Novacyt (NYCT:AIM) has acquired IT-IS International, the exclusive manufacturer of the group’s q16 and q32 rapid polymerase chain reaction (PCR) instruments, for £10.1 million in cash. The shares rallied 5% to 870p on the news.

    Management wasted no time in putting into action its recently announced strategy to strengthen the company’s intellectual property (IP) portfolio and expand its core capabilities.

    Today’s deal will result in the company becoming a diagnostic platform instrument and reagent manufacturer, significantly increasing the capacity of IT-IS to meet the expected demand for its q16 and q32 PCR instruments. The new combination will also allow Novacyt to reduce its cost of goods and therefore improve the gross margin of its instrument sales.

    GREAT DEAL FOR SHAREHOLDERS

    Cash on IT-IS’s balance sheet of £3.6 million reduces the purchase cost to £6.5 million which represents only 8 times IT-IS’s net profit for the year ended December 2019.

    Revenues for the first six months of 2020 increased significantly to an annualised £5 million from £3.9 million with an improved gross margin of 58%, due to higher levels of activity driven by the COVID-19 pandemic, making the deal even more attractive.

    An earn-out of up to £1.9 million in cash is payable to the directors of IT-IS over the next two years, subject to certain manufacturing targets being achieved.

    Chief executive Graham Mullis commented: ‘Novacyt has been working with IT-IS for more than five years through the sale of the q16 and q32 instruments. During this time, IT-IS has proven the quality, performance and reliability of its mobile PCR platform. This acquisition ensures that Novacyt is in a strong position to fulfil the growing market demands for rapid
70.511 Posts
Pagina: «« 1 ... 1540 1541 1542 1543 1544 ... 3526 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.